ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial - Ranson,M.; Hammond,L.A.; Ferry,D. (J Clin Oncol, 2002)